Fadrozole for Breast Cancer
From New Treatment Wiki
CGS16949A (Fadrozole) demonstrated its ability to inhibit estrogens in women but unexpectedly uncovered aldosterone-blocking properties. This limited the doses of fadrozole that could be given to block aromatase more effectively than with AG or formestane.
Although approved for use in Japan, fadrozole never achieved substantial usage. More potent and selective aromatase inhibitors were clearly needed. Using an array of resources, the pharmaceutical companies then used structure/function analysis, animal models, and sophisticated hormone assays to identify lead compounds. This resulted in the development and licensing of two nonsteroidal reversible inhibitors, anastrozole and letrozole, and one mechanism-based steroidal inhibitor, exemestane.
